On Wednesday, Aileron Therapeutics Inc (NASDAQ; ALRN) revealed topline data from Cohort 2 of its Phase 1b trial of safety and ...

Aileron Therapeutics (ALRN) announced positive topline data from Cohort 2 of its Phase 1b clinical trial evaluating the safety and tolerability ...

Ph.D., President and Chief Executive Officer of Aileron. "Additionally, we saw dose dependent effects in five biomarkers ...

(RTTNews) - Aileron Therapeutics, Inc. (ALRN), Wednesday announced positive topline data from the cohort 2 of Phase 1b study evaluating LTI-03 in patients with idiopathic pulmonary fibrosis (IPF).

Aileron Therapeutics, Inc. (NASDAQ:ALRN – Get Free Report) was the target of a significant decline in short interest in October.As of October 15th, there was short interest totalling 255,600 ...

AUSTIN, Texas and NEW YORK, Oct. 31, 2024 /PRNewswire/ -- Aileron Therapeutics, Inc. ("Aileron") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines ...

Short interest in Aileron Therapeutics Inc (NASDAQ:ALRN) decreased during the last reporting period, falling from 297.75K to 255.55K. This put 1.18% of the company's publicly available shares short.

Advancium will evaluate ALRN-6924 as a potential therapy for retinoblastoma, a rare but devastating pediatric cancer of the eye AUSTIN, Texas and NEW YORK, Oct. 31, 2024 /PRNewswire/ -- Aileron ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...